Successful Miltefosine Treatment of Post-Kala-Azar Dermal Leishmaniasis Occurring During Antiretroviral Therapy.

Hdl Handle:
http://hdl.handle.net/10144/18245
Title:
Successful Miltefosine Treatment of Post-Kala-Azar Dermal Leishmaniasis Occurring During Antiretroviral Therapy.
Authors:
Belay, A D; Asafa, Y; Mesure, J; Davidson, R N N
Journal:
Annals of Tropical Medicine and Parasitology
Abstract:
The first two patients to be treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL) are reported. One was a 26-year-old Ethiopian man who had been treated with sodium stibogluconate, for relapsing visceral leishmaniasis (VL), four times between August 2002 and March 2004. In January 2004 this patient was found to be seropositive for HIV and began antiretroviral treatment with stavudine, lamivudine and nevirapine. Five months later he developed clinical PKDL, with extensive cutaneous, conjunctival and oral mucosal involvement. The second patient was a 42-year-old Ethiopian man who was treated for relapsing VL in November 2003. He too was subsequently found to be seropositive for HIV and was treated with stavudine, lamivudine and nevirapine from May 2004. He developed a nodular rash of PKDL over his face and upper body 2 weeks after starting the antiretroviral therapy. Treatment of both patients with oral miltefosine, at 100 mg/day for 28 days, led to the complete regression of their PKDL lesions. When checked 3-6 months after the end of the miltesofine treatment, neither patient showed any signs of VL, PKDL or other HIV-associated disease.
Affiliation:
Médecins Sans Frontières - Netherlands, Plantage Middenlaan 14, P.O. Box 10014, 1001 EA Amsterdam, The Netherlands.
Publisher:
Published by: Maney Publishing
Issue Date:
Apr-2006
URI:
http://hdl.handle.net/10144/18245
DOI:
10.1179/136485906X91440
PubMed ID:
16630379
Additional Links:
http://www.maney.co.uk/journals/atmp
Language:
en
ISSN:
0003-4983
Appears in Collections:
Leishmaniasis/Kala Azar

Full metadata record

DC FieldValue Language
dc.contributor.authorBelay, A D-
dc.contributor.authorAsafa, Y-
dc.contributor.authorMesure, J-
dc.contributor.authorDavidson, R N N-
dc.date.accessioned2008-02-14T11:14:03Z-
dc.date.available2008-02-14T11:14:03Z-
dc.date.issued2006-04-
dc.identifier.citationSuccessful Miltefosine Treatment of Post-Kala-Azar Dermal Leishmaniasis Occurring During Antiretroviral Therapy. 2006, 100 (3):223-7 Ann. Trop. Med. Parasitol.en
dc.identifier.issn0003-4983-
dc.identifier.pmid16630379-
dc.identifier.doi10.1179/136485906X91440-
dc.identifier.urihttp://hdl.handle.net/10144/18245-
dc.description.abstractThe first two patients to be treated with miltefosine for post-kala-azar dermal leishmaniasis (PKDL) are reported. One was a 26-year-old Ethiopian man who had been treated with sodium stibogluconate, for relapsing visceral leishmaniasis (VL), four times between August 2002 and March 2004. In January 2004 this patient was found to be seropositive for HIV and began antiretroviral treatment with stavudine, lamivudine and nevirapine. Five months later he developed clinical PKDL, with extensive cutaneous, conjunctival and oral mucosal involvement. The second patient was a 42-year-old Ethiopian man who was treated for relapsing VL in November 2003. He too was subsequently found to be seropositive for HIV and was treated with stavudine, lamivudine and nevirapine from May 2004. He developed a nodular rash of PKDL over his face and upper body 2 weeks after starting the antiretroviral therapy. Treatment of both patients with oral miltefosine, at 100 mg/day for 28 days, led to the complete regression of their PKDL lesions. When checked 3-6 months after the end of the miltesofine treatment, neither patient showed any signs of VL, PKDL or other HIV-associated disease.en
dc.language.isoenen
dc.publisherPublished by: Maney Publishing-
dc.relation.urlhttp://www.maney.co.uk/journals/atmp-
dc.rightsArchived on this site with the kind permission of Maney Publishingen
dc.subject.meshAdministration, Oralen
dc.subject.meshAdulten
dc.subject.meshAnti-Retroviral Agentsen
dc.subject.meshAntiprotozoal Agentsen
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshHIV Seropositivityen
dc.subject.meshHumansen
dc.subject.meshLeishmaniasis, Cutaneousen
dc.subject.meshLeishmaniasis, Visceralen
dc.subject.meshMaleen
dc.subject.meshPhosphorylcholineen
dc.subject.meshTreatment Outcomeen
dc.titleSuccessful Miltefosine Treatment of Post-Kala-Azar Dermal Leishmaniasis Occurring During Antiretroviral Therapy.en
dc.contributor.departmentMédecins Sans Frontières - Netherlands, Plantage Middenlaan 14, P.O. Box 10014, 1001 EA Amsterdam, The Netherlands.en
dc.identifier.journalAnnals of Tropical Medicine and Parasitologyen
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.